Press Releases

Date	Title	PDF Version
Dec 11, 2017	Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting
Dec 07, 2017	Alexion and Halozyme Enter License Agreement for ENHANZE Technology
Nov 27, 2017	Alexion to Present at the Citi 2017 Global Healthcare Conference
Nov 09, 2017	Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service
Nov 08, 2017	Alexion Appoints Francois Nader, M.D. to its Board of Directors
Nov 06, 2017	Alexion Receives New Japanese Patent for Soliris® (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio
Nov 03, 2017	New Interim Data Presented at NASPGHAN 2017 Meeting Show Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Kanuma® (sebelipase alfa)
Nov 01, 2017	New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting
Oct 30, 2017	Alexion to Present at the 26th Annual Credit Suisse Healthcare Conference
Oct 26, 2017	Alexion Reports Third Quarter 2017 Results

Search